Max Healthcare Institute Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Max Healthcare’s record carries an unbroken chain of unmodified audit opinions and operating cash flow that has covered reported profit in every one of the last five years. Three things deserve attention: a web of related‑party loans and guarantees that the company does not treat as material, goodwill of ₹2,455 crore that has never been impaired despite losses at acquired entities, and consolidated borrowings that have risen to ₹3,478 crore while merger‑driven deferred‑tax credits repeatedly lift reported profit.

Key findings

  1. Goodwill stood at ₹2,455 crore and has never been impaired, even as acquired entities lose money Major - Consolidated goodwill stood at ₹2,454.66 crore at March 31, 2021 and has never been impaired through FY26. Starlit Medical Centre reported a total comprehensive loss of ₹21.02 crore for FY24, and Alexis Multi‑Speciality Hospital reported a loss of ₹3.18 crore for FY24. The auditor has identified goodwill impairment as a Key Audit Matter in the consolidated financial statements for FY21, FY23, and FY24.
  2. Merger‑driven deferred‑tax credits and contingent‑consideration remeasurements have repeatedly boosted reported profit Major - A one‑time deferred‑tax gain of ₹141 crore arose in FY26 from the amalgamation of two wholly owned subsidiaries. In FY23, a deferred‑tax credit of ₹282.5 crore was recognised upon the voluntary liquidation of Saket City Hospitals Limited. Other income rose to ₹163 crore in FY26, with the increase attributed primarily to reassessment of contingent consideration.
  3. Multiple contested tax demands and a cancelled land allotment are under litigation, with no provisions made Minor - HSVP cancelled the allotment of 6.11 acres in Gurugram (allotted for ₹95.51 crore) on December 21, 2022; the company challenged the cancellation in the Punjab & Haryana High Court, which ordered status quo. A GST order dated December 30, 2025 alleged excess Input Tax Credit with a demand of ₹33.66 crore, interest of ₹18.17 crore, and penalty of ₹3.36 crore. The company has not provided for these disputed amounts based on management’s assessment of favourable outcomes.
  4. A multi‑year acquisition‑and‑restructuring treadmill has left a shifting subsidiary map Minor - As of March 31, 2026, the company had 10 subsidiaries and 3 controlled “Silo” entities consolidated under Ind AS 110 without ownership. On May 18, 2026, the company acquired a 58.28% stake in Kalinga Hospital Ltd for ₹297.97 crore and signed a share purchase agreement for a staggered 100% acquisition of Yerawada Properties Pvt. Ltd.. Crosslay Remedies Limited was merged into Jaypee Healthcare Limited effective December 15, 2025, with the merged entity subsequently renamed Crosslay Remedies Limited, and ET Planners Private Limited was dissolved effective March 25, 2026.
  5. Promoter governance shows a family relationship at the top and significant shareholder dissent on director and remuneration resolutions Minor - Mr Abhay Soi, Chairman and Managing Director, is the son‑in‑law of Mr Anil Kumar Bhatnagar, Non‑Executive Non‑Independent Director. At the 22nd AGM on September 27, 2023, the resolution for a one‑time performance bonus of ₹3.50 crore to Mr Soi received 23.575% votes against, with public institutions voting 32.452% against. At the 21st AGM on September 26, 2022, the special resolution for the ESOP Scheme 2022 received 19.278% votes against.
  6. Audit opinions are unmodified, but audit‑trail gaps in accounting software recur across years Minor - The statutory auditor issued an unmodified opinion on both standalone and consolidated financial statements for every year from FY20 through FY26. For FY26, the audit trail was not enabled for direct database changes in one accounting software used by the Holding Company and six subsidiaries because the functionality was not available. The consolidated audit opinion for FY26 relies on other auditors for three subsidiaries with total assets of ₹43.47 crore.
  7. Revenue recognition is routine, and management asserts full recoverability of growing receivables from partner facilities Clean - The Group has a single reportable segment and no external customer accounts for 10% or more of revenue across all years FY20-FY26. Standalone receivables from partner healthcare facilities grew from ₹326.77 crore at March 2021 to ₹683.24 crore at March 2025; management concluded they are fully recoverable with no impairment in each year.
  8. Operating cash flow consistently covers profit, but free cash flow is absorbed by an expanding capital programme Clean - Consolidated CFO exceeded PAT in each of the last five years: FY26 CFO ₹1,633 crore vs PAT ₹1,442 crore (1.13×), FY25 ₹1,438 crore vs ₹1,076 crore (1.34×), FY24 ₹1,122 crore vs ₹1,058 crore (1.06×). Consolidated free cash flow fell from ₹877 crore in FY23 to ₹165 crore in FY26. The Board recommended a final dividend of ₹2 per share for FY26, a payout ratio of 27.2% of standalone PAT.

What to watch

Bottom line: This is a disclosed and audited record with real cash conversion and an unbroken run of clean audit opinions. The risk sits in three places: the shifting subsidiary map that includes controlled entities consolidated without ownership and a post‑year‑end acquisition, the ₹2,455‑crore goodwill balance that has never been tested by an impairment charge, and the merger‑driven deferred‑tax credits that have repeatedly lifted reported profit. Watch whether the goodwill assumption holds as acquired entities continue to lose money, and whether the Eqova put option crystallises into a cash outflow.